Clinical trial NCT01068873: Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)
Official title: Kaletra and Maraviroc in Antiretroviral Therapy-Naïve Patients - KALMAR Study -Version 1.0 Amendment 2
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: HIV Infections
Keywords: HIV
Protease Inhibitor
CCR5 Co-receptor Antagonist
treatment naive
Lead sponsor: Temple University
Sponsor class: OTHER
Collaborators: name: Abbott
name: Pfizer
First posted: 2010-02-15
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary objective of this pilot study is to assess the efficacy of lopinavir/ritonavir (Kaletra, a protease inhibitor, PI) when used in combination with maraviroc (Selzentry, an HIV entry inhibitor) for the treatment of antiretroviral naïve HIV infected patients. Twenty patients will be enrolled and studied for 48 weeks.

Detailed description: As patients with HIV are living longer it is important to explore antiretroviral treatments which may reduce the development of long term complications while preserving future HIV treatment options. This trial explores an antiretroviral treatment regimen which does not include the nucleoside reverse transcriptase inhibitor class which is thought to have long-term toxicity. This is a non-randomized, open label trial in participants meeting entry requirements.

Participants will be evaluated at screening, baseline,and weeks 4, 8, 12, 24, 36, and 48 to include clinical assessments as well as laboratory assessments.

An interim analysis will be performed when all patients have reached the week 24 visit.

Eligibility criteria: Inclusion Criteria:

* The patient has signed and dated approved informed consent form.
* There is confirmed laboratory diagnosis of HIV infection (positive ELISA HIV antibody test confirmed by Western blot, p24 antigen assay, quantitative HIV-1 RNA assay, or HIV culture).
* The patient is at least 18 years of age.
* ART-naïve, lopinavir/ritonavir susceptible on genotypic testing, CCR5-tropic virus on Trofile testing (ESTA).
* Negative pregnancy test within 72 hours prior to start of study for women of childbearing potential.
* Females of childbearing potential and males must utilize effective barrier contraception.
* HIV RNA greater than 1,000 copies per mL at entry.
* Liver enzymes (AST, ALT) \< 3 times the upper limit of normal.

Exclusion Criteria:

* Patients who are pregnant or breast-feeding.
* Active alcohol or substance abuse sufficient, in the Investigator's opinion that makes compliance to the study protocol unlikely.
* Suspected or active HIV-related opportunistic infection or condition requiring acute therapy within 30 days of entry into the trial.
* Patients on therapy for hepatitis B.
* Patients with hepatitis B surface antigen, or any evidence of active hepatitis B such as positive hepatitis B DNA and/or presence of hepatitis e antigen or e antibody.
* Acute hepatitis B or C within 60 days of entry.
* Patients harboring preexistent co-receptor CXCR4 tropic or dual-or mixed-tropic HIV.
* Patients harboring HIV resistant to lopinavir/ritonavir on genotypic testing.
* The presence of decompensated heart failure, myocardial infarction within 1 year, bypass surgery, severe vascular disease, or active hepatobiliary disease.
* Concomitant use of rifampin, ergot derivatives (i.e. dihydroergotamine, ergotamine), cisapride, lovastatin, simvastatin, triazolam, orally administered midazolam, carbamazepine, phenytoin, St. John's wort, ketoconazole, itraconazole, clarithromycin, telithromycin, amiodarone, bepridil, flecainide, propafenone, quinidine, voriconazole or nefazodone.
* Patients with concomitant diagnosis of malignancy or cancer other than basal cell carcinoma within the past 5 years.
* Concomitant use of investigational agents including the use of any investigational vaccines.
* Any other clinical conditions or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for study, or unable to comply with the dosing requirements.

Primary outcomes:
measure: Assess Proportion of Participants With HIV RNA Levels <50 and < 400 Copies/mL.
timeFrame: week 48
Secondary outcomes:
measure: Number of Participants With HIV RNA < 50 and <400 Copies/ml.
timeFrame: week 24
measure: Assess the Proportion of Participants at Study Termination With VL < 50 Copies/ml.
timeFrame: week 48
measure: Determine the Time to Viral Suppression (VL < 50 Copies/ml).
timeFrame: 48 weeks
measure: Determine the Median Change in VL From Baseline to Week 24, to Week 48 and to Study Termination.
timeFrame: week 24, week 48
measure: Assess the Changes in CD4+ T Cell Count.
timeFrame: week 24, 48
measure: Assess Development of HIV Resistance Mutations and in HIV Co-receptor Tropism Changes in Participants Who Develop Virologic Rebound.
timeFrame: week 48
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Temple General Internal Medicine
state: Pennsylvania
Study officials:
affiliation: Temple University
name: Mary van den Berg-Wolf, MD
role: PRINCIPAL_INVESTIGATOR
References: